Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date

References

• Baria K, De Toni EN, Yu B, et al. Worldwide incidence and mortality of biliary tract cancer. Gastro Hep Adv. 2022;1(4):618–626. doi:10.1016/j.gastha.2022.04.007
   Google Scholar
• Ellington TD, Momin B, Wilson RJ, et al. Incidence and mortality of cancers of the biliary tract, gallbladder, and liver by sex, age, race/ethnicity, and stage at diagnosis: United States, 2013 to 2017. Cancer Epidemiol Biomarkers Prev. 2021;30(9):1607–1614. doi:10.1158/1055-9965.EPI-21-0265
   PubMed Web of Science ®Google Scholar
• Jiang Y, Jiang L, Li F, et al. The epidemiological trends of biliary tract cancers in the United States of America. BMC Gastroenterol. 2022;22(1):22. doi:10.1186/s12876-022-02094-3
   PubMed Web of Science ®Google Scholar
• Tella SH, Wieczorek M, Hodge D, et al. A glimpse into the future of cholangiocarcinoma: predicting the future incidence based on the current epidemiological data. J Clin Oncol. 2023;41(4_suppl):616. doi:10.1200/JCO.2023.41.4_suppl.616
   Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–1281.
   PubMed Web of Science ®Google Scholar
• Shroff RT, Guthrie KA, Scott AJ, et al. SWOG 1815: a Phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. J Clin Oncol. 2023;41(4_suppl):LBA490–LBA490. doi:10.1200/JCO.2023.41.4_suppl.LBA490
   Google Scholar
• marc PJ, Desrame J, Edeline J, et al. Modified FOLFIRINOX Versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a Randomized Phase II study. J Clin Oncol. 2022;40(3):262–271. doi:10.1200/JCO.21.00679
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40(4_suppl):379. doi:10.1200/JCO.2022.40.4_suppl.379
   Web of Science ®Google Scholar
• Greten TF, Schwabe R, Bardeesy N, et al. Immunology and immunotherapy of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2023;20(6):349–365. doi:10.1038/s41575-022-00741-4
   PubMed Web of Science ®Google Scholar
• Zhou G, Sprengers D, Mancham S, et al. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules. J Hepatol. 2019;71(4):753–762. doi:10.1016/j.jhep.2019.05.026
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Dunn C, Peppa D, Khanna P, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology. 2009;137(4):1289–1300. doi:10.1053/j.gastro.2009.06.054
   PubMed Web of Science ®Google Scholar
• Dustin LB. Innate and adaptive immune responses in chronic HCV infection. Curr Drug Targets. 2017;18(7):826–843. doi:10.2174/1389450116666150825110532
   PubMed Web of Science ®Google Scholar
• Gao M, Huang A, Sun Z, et al. Granulocytic myeloid-derived suppressor cell population increases with the severity of alcoholic liver disease. J Cell Mol Med. 2019;23(3):2032–2041. doi:10.1111/jcmm.14109
   PubMed Web of Science ®Google Scholar
• Job S, Rapoud D, Dos Santos A, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology. 2020;72(3):965–981. doi:10.1002/hep.31092
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010. doi:10.1038/ng.3375
   PubMed Web of Science ®Google Scholar
• Sabbatino F, Villani V, Yearley JH, et al. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016;22(2):470–478. doi:10.1158/1078-0432.CCR-15-0715
   PubMed Web of Science ®Google Scholar
• Sun D, Ma J, Wang J, et al. Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. Cancer Immunol Immunother. 2019;68(9):1527–1535. doi:10.1007/s00262-019-02386-w
   PubMed Web of Science ®Google Scholar
• Ricci AD, D’alessandro R, Rizzo A, et al. Durvalumab in advanced cholangiocarcinoma: is someone knocking down the door? Immunotherapy. 2023;15(7):477–486. doi:10.2217/imt-2022-0301
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ladoire S, Coukos G, et al. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol off J Eur Soc Med Oncol. 2015;26(9):1813–1823. doi:10.1093/annonc/mdv209
   PubMed Web of Science ®Google Scholar
• Fournier C, Rivera Vargas T, Martin T, et al. Immunotherapeutic properties of chemotherapy. Curr Opin Pharmacol. 2017;35:83–88. doi:10.1016/j.coph.2017.05.003
   PubMed Web of Science ®Google Scholar
• Stewart R, Morrow M, Hammond SA, et al. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. Cancer Immunol Res. 2015;3(9):1052–1062. doi:10.1158/2326-6066.CIR-14-0191
   PubMed Web of Science ®Google Scholar
• Lutzky J, Antonia SJ, Blake-Haskins A, et al. A phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumors. J Clin Oncol. 2014;32(15_suppl):3001. doi:10.1200/jco.2014.32.15_suppl.3001
   Google Scholar
• Oh DY, Lee KH, Lee DW, et al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. lancet Gastroenterol Hepatol. 2022;7(6):522–532. doi:10.1016/S2468-1253(22)00043-7
   PubMed Web of Science ®Google Scholar
• D-Y O, Ruth A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;3:1.
   Google Scholar
• Rimini M, Fornaro L, Lonardi S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. Liver Int. 2023;43(8):1803–1812. doi:10.1111/liv.15641
   PubMed Web of Science ®Google Scholar
• D-Y O, He AR, Qin S, et al. Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol. 2022;33:S1462–S1463. doi:10.1016/j.annonc.2022.10.114
   Google Scholar
• Valle JW, Qin S, Antonuzzo L, et al. Impact of mutation status on efficacy outcomes in TOPAZ-1: a phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC). Ann Oncol. 2022;33:S1457. doi:10.1016/j.annonc.2022.10.104
   Web of Science ®Google Scholar
• Burris III HA, Okusaka T, Vogel A. Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. J Clin Oncol. 2022;40(16_suppl):4070. doi:10.1200/JCO.2022.40.16_suppl.4070
   Web of Science ®Google Scholar
• Zhao Q, Xie R, Zhong W, et al. Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial. Cost Eff Resour Alloc. 2023;21(1):21. doi:10.1186/s12962-023-00430-2
   PubMed Web of Science ®Google Scholar
• Ye ZM, Xu Z, Li H, et al. Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer. Front Public Health. 2023;11:2.
   Web of Science ®Google Scholar
• Piha-Paul SA, Oh DY, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE −158 and KEYNOTE −028 studies. Int J Cancer. 2020;147(8):2190–2198. doi:10.1002/ijc.33013
   PubMed Web of Science ®Google Scholar
• Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853–1865. doi:10.1016/S0140-6736(23)00727-4
   PubMed Web of Science ®Google Scholar
• Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. lancet Gastroenterol Hepatol. 2019;4(8):611–621. doi:10.1016/S2468-1253(19)30086-X
   PubMed Web of Science ®Google Scholar
• Feng K, Liu Y, Zhao Y, et al. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. J Immunother Cancer. 2020;8(1):e000367. doi:10.1136/jitc-2019-000367
   PubMed Web of Science ®Google Scholar
• Sahai V, Griffith KA, Beg MS, et al. A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: bilT −01. Cancer. 2022;128(19):3523–3530. doi:10.1002/cncr.34394
   PubMed Web of Science ®Google Scholar
• Beri N. Immune checkpoint inhibitors in cholangiocarcinoma. Immunotherapy. 2023;15(7):541–551. doi:10.2217/imt-2022-0288
   PubMed Web of Science ®Google Scholar
• Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol off J Eur Soc Med Oncol. 2022;33(9):929–938. doi:10.1016/j.annonc.2022.05.519
   PubMed Web of Science ®Google Scholar
• Ahn S, chan LJ, Shin DW, et al. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Sci Rep. 2020;10(1):10. doi:10.1038/s41598-019-56089-4
   PubMedGoogle Scholar
• Liddell SS, Chakrabarti S, Wintheiser GA, et al. Tumor mutational burden is a potential predictive biomarker for response to immune checkpoint inhibitors in patients with advanced biliary tract cancer. JCO Precis Oncol. 2022;6:2.
   Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers. 2021;13(3):1–11. doi:10.3390/cancers13030558
   Web of Science ®Google Scholar
• Frega G, Cossio FP, Banales JM, et al. Lacking immunotherapy biomarkers for biliary tract cancer: a comprehensive systematic literature review and meta-analysis. Cells. 2023;12(16):2098. doi:10.3390/cells12162098
   PubMed Web of Science ®Google Scholar
• Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol. 2019;10(4):652–662. doi:10.21037/jgo.2018.08.18
   PubMed Web of Science ®Google Scholar
• Zhou B, Gao Y, Zhang P, et al. Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies. Front Immunol. 2021;2:12.
   Google Scholar
• Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs. 2021;30(4):343–350. doi:10.1080/13543784.2021.1897102
   PubMed Web of Science ®Google Scholar
• Kim DW, Kim Y, Kovari BP, et al. Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer. Eur J Cancer. 2022;176:171–180. doi:10.1016/j.ejca.2022.09.014
   PubMed Web of Science ®Google Scholar
• Chen X, Wang D, Liu J, et al. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes. J Immunother Cancer. 2021;2:9.
   Google Scholar
• Lo JH, Agarwal R, Goff LW, et al. Immunotherapy in biliary tract cancers: current standard-of-care and emerging strategies. Cancers. 2023;16(1):15. doi:10.3390/cancers16010015
   PubMedGoogle Scholar
• Merters J, Lamarca A. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma. J Hepatol. 2023;78(3):652–657. doi:10.1016/j.jhep.2022.11.005
   PubMed Web of Science ®Google Scholar
• Storandt MH, Kurniali PC, Mahipal A, et al. Targeted therapies in advanced cholangiocarcinoma. Life. 2023;13(10):2066. doi:10.3390/life13102066
   PubMedGoogle Scholar
• Zhang W, Shi J, Wang Y, et al. Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers. Cancer Immunol Immunother. 2021;70(4):1001–1014. doi:10.1007/s00262-020-02745-y
   PubMed Web of Science ®Google Scholar
• Demols A, Bucalau A-M, Mans L. The path to personalized treatment in advanced and metastatic biliary tract cancers: a review of new targeted therapies and immunotherapy. Curr Opin Oncol. 2022;34(4):403–411. doi:10.1097/CCO.0000000000000850
   PubMed Web of Science ®Google Scholar
• Dong X, Zhang Z, Zhang Q, et al. Triple therapy in biliary tract cancers: gemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy. J Cancer Res Clin Oncol. 2023;149:1917–1927. doi:10.1007/s00432-022-04166-z
   PubMed Web of Science ®Google Scholar
• Zhang W, Xiang D, Lu C, et al. GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy in patients with biliary tract cancers. J Clin Oncol. 2022;40(16_suppl):e16133–e16133. doi:10.1200/JCO.2022.40.16_suppl.e16133
   Web of Science ®Google Scholar
• Zhang Q, Liu X, Wei S, et al. Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: a single-arm, open-label, phase II study. Front Oncol. 2021;3:11.
   Google Scholar
• Lin J, Yang X, Long J, et al. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr. 2020;9(4):414–424. doi:10.21037/hbsn-20-338
   PubMed Web of Science ®Google Scholar
• Shi C, Li Y, Yang C, et al. Lenvatinib plus programmed cell death protein-1 inhibitor beyond first-line systemic therapy in refractory advanced biliary tract cancer: a real-world retrospective study in China. Front Immunol. 2022;2:13.
   Google Scholar
• Zhu C, Xue J, Wang Y, et al. Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer. Front Immunol. 2023;2:14.
   Google Scholar
• Doki Y, Ueno M, Hsu CH, et al. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer. Cancer Med. 2022;11(13):2550–2560. doi:10.1002/cam4.4593
   PubMed Web of Science ®Google Scholar
• Boilève A, Hilmi M, Gougis P, et al. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. Eur J Cancer. 2021;143:55–63. doi:10.1016/j.ejca.2020.10.027
   PubMed Web of Science ®Google Scholar
• Elias C, Zeidan YH, Bouferraa Y, et al. A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO). BMC Cancer. 2022;22(1). doi:10.1186/s12885-022-10373-1
   PubMed Web of Science ®Google Scholar
• Maithel SK, Keilson JM, Cao HST, et al. NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable, high-risk intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2023;30(11):6558–6566. doi:10.1245/s10434-023-13809-5
   PubMed Web of Science ®Google Scholar